Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Naltrekson untuk ketergantungan opioid

Penilaian teknologi kesehatan PTK-N07BB04 Draf untuk telaah Diperbarui 31 Mei 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Naltrekson disertai dukungan psikososial terpantauRp 47,9 juta3,0104,95
dukungan psikososial sajaRp 48,9 juta2,9584,93
Selisih-Rp 1,0 juta0,052-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
-8-5-2025-0,050,000,050,100,15Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta98,7%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-6-4-20246interventions psychosocial support alone transition rate multipliers abstinent in treatment to relapsed opioid useinterventions psychosocial support...interventions naltrexone supervised abstinence programme transition rate multipliers abstinent in treatment to relapsed opioid useinterventions naltrexone supervise...utility values relapsed opioid useutility values relapsed opioid useinterventions naltrexone supervised abstinence programme transition rate multipliers abstinent in treatment to discontinued treatmentinterventions naltrexone supervise...interventions psychosocial support alone transition rate multipliers abstinent in treatment to discontinued treatmentinterventions psychosocial support...interventions naltrexone supervised abstinence programme drug cost idr per courseinterventions naltrexone supervise...annual care costs idr relapsed opioid useannual care costs idr relapsed opi...utility values abstinent in treatmentutility values abstinent in treatm...interventions psychosocial support alone transition rate multipliers relapsed opioid use to abstinent in treatmentinterventions psychosocial support...interventions naltrexone supervised abstinence programme transition rate multipliers relapsed opioid use to abstinent in treatmentinterventions naltrexone supervise...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • A/B/C disagreement is treated as a reviewer priority flag; do not use the consensus as final policy evidence without health economist review.
  • Use Indonesian procurement and reimbursement status before any policy interpretation.
  • Scenario analysis should test local standard-of-care comparators and access restrictions.
  • Threshold uses 1x and 3x GDP proxy only; InaHTAC may use different decision rules.
  • The two-agent spread should be treated as a triage signal for manual reviewer focus.